Compare Macy's Inc (M) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Recursion Pharmaceuticals Inc — how do they compare? Macy's Inc trades at $23.6 (market cap $6.13B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Macy's Inc is far larger — about 4× Recursion Pharmaceuticals Inc's market cap, and Macy's Inc pays a 3.29% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| M | RXRX | |
|---|---|---|
Market Cap | $6.13B | $1.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.96 | $6.79 |
52-Week Low | $11.90 | $2.84 |
Enterprise Value | $9.95B | $946.50M |
Dividend Yield | 3.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $23.39, down 1.22% on the day, with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics including a P/E of 9.79 and P/S of 0.29, while recent earnings have consistently beaten expectations. Positive sentiment is driven by the 'Bold New Chapter' turnaround strategy, with Berkshire Hathaway's new 3.04 million-share position adding institutional confidence.
The outlook remains cautiously optimistic with a consensus price target of $24.83 offering 6% upside potential. Key opportunities include luxury brand expansion and digital transformation, while risks involve margin pressure from store closures and macroeconomic sensitivity. The stock presents value characteristics with growth catalysts from operational improvements.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
